AdvisorShares Psychedelics ETF (PSIL)

Relmada stated that the therapy showed a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer.

The company stated that, following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.

The study showed statistically significant and clinically meaningful reductions in depressive symptoms at two weeks in participants treated with SPL026 compared with placebo, the company said.

COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

Jefferies sees restrictions around non-recreational psychedelics eventually loosen up.

The company announced the pricing of a public offering of 80 million shares of its common stock and said that the offering will extend its cash runway through at least the first half of 2028.

Quantum Biopharma's subsidiary, Huge Biopharma Australia, has cleared a regulatory milestone for its neuroprotective compound, Lucid-MS, in a Phase 1 trial.

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.

Last week had Wall Street facing volatility, tech earnings disappointments, mixed labor data, and rising inflation fears. Gold hit record highs.

Momentum investors looking to start 2025 off on good footing might look no further than these high-flying ETFs, each of which has returned 14% or more in 2025.

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.

The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.

In this article, we have highlighted five top-performing ETFs from different sectors that were the leaders in the fourth quarter.

Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder.

In this article, we have highlighted five top-performing ETFs from different sectors that were the leaders over the past month.

In this article, we have highlighted three ETFs each from the best and worst-performing zones in the first half of 2024.

After the worst monthly decline in many months in April, global stock markets have staged a nice comeback on renewed Fed rate cut bets, ongoing artificial intelligence (AI) developments and strong corporate profits.

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.